Workflow
YSB(09885)
icon
Search documents
药师帮(09885) - 截至二零二五年十一月三十日止月份之股份发行人的证券变动月报表
2025-12-02 09:08
FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致:香港交易及結算所有限公司 公司名稱: 藥師幫股份有限公司 (於開曼群島註冊成立之有限公司) 呈交日期: 2025年12月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09885 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | USD | 0.0000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 20,000,000,000 | USD | 0.0000025 | USD | | 50,000 | ...
智通港股股东权益披露|11月25日
智通财经网· 2025-11-25 00:06
Core Insights - The latest shareholder equity disclosures for Baixinan-B (02185), Yaoshibang (09885), and Shiyao Group (01093) were conducted on November 25, 2025 [1] Group 1: Baixinan-B (02185) - Winning Powerful Limited increased its holdings from 45.7756 million shares to 45.7856 million shares, representing a holding percentage change from 19.42% to 19.43% [2] - Wang Philip Li also increased his holdings from 84.9577 million shares to 84.9677 million shares, with a holding percentage change from 36.04% to 36.05% [2] Group 2: Yaoshibang (09885) - Chen Fei increased his holdings from 9 million shares to 9.15 million shares, with a holding percentage change from 1.32% to 1.34% [2] Group 3: Shiyao Group (01093) - Cai Dongchen increased his holdings from 2.872 billion shares to 2.887 billion shares, with a holding percentage change from 24.93% to 25.06% [2]
执行董事陈飞增持药师帮15万股 每股作价6.75港元
Zhi Tong Cai Jing· 2025-11-24 11:10
香港联交所最新数据显示,11月24日,执行董事陈飞增持药师帮(09885)15万股,每股作价6.75港元,总 金额为101.25万港元。增持后最新持股数目为915万股,持股比例为1.34%。 ...
执行董事陈飞增持药师帮20万股 每股作价6.964港元
Zhi Tong Cai Jing· 2025-11-21 07:34
Group 1 - The executive director Chen Fei increased his stake in Yaoshibang (09885) by purchasing 200,000 shares at a price of HKD 6.964 per share, totaling approximately HKD 1.3928 million [1] - After the purchase, the total number of shares held by Chen Fei is approximately 9 million, representing a holding percentage of 1.32% [1]
执行董事陈飞增持药师帮(09885)20万股 每股作价6.964港元
智通财经网· 2025-11-21 07:28
智通财经APP获悉,香港联交所最新数据显示,11月20日,执行董事陈飞增持药师帮(09885)20万股,每 股作价6.964港元,总金额约为139.28万港元。增持后最新持股数目约为900万股,持股比例为1.32%。 ...
智通港股股东权益披露|11月21日
智通财经网· 2025-11-21 00:06
Core Insights - The latest shareholder equity disclosures for several companies, including Ajisen (China) (00538), Zai Lab Limited (09939), Yaoshi Bang (09885), and Kwansei Holdings (01925), were reported on November 21, 2025 [1] Group 1: Shareholder Changes - Ajisen (China) saw a complete divestment by Ren Yuwen, reducing holdings from 95,000 shares to 0 shares, resulting in a holding percentage change from 0.01% to 0% [2] - Zai Lab Limited had an increase in holdings by Tong Youzhi from 52,200,300 shares to 52,500,300 shares, with a holding percentage change from 11.15% to 11.21% [2] - Another increase in Zai Lab Limited was reported for KT International, which raised its holdings from 49,700,300 shares to 50,000,300 shares, changing the holding percentage from 10.62% to 10.68% [2] - Yaoshi Bang experienced a slight increase in holdings by Chen Fei from 8,800,000 shares to 9,000,000 shares, with a holding percentage change from 1.29% to 1.32% [2] - Kwansei Holdings reported an increase in holdings by Tian Dong from 3,895,400 shares to 4,443,400 shares, changing the holding percentage from 0.96% to 1.10% [2]
药师帮(09885.HK)11月20日耗资140万港元回购20万股
Ge Long Hui· 2025-11-20 11:06
Core Viewpoint - The company, Yaoshi Bang (09885.HK), announced a share buyback of 200,000 shares at a cost of HKD 1.4 million on November 20 [1] Related Events - On November 20, Yaoshi Bang (09885.HK) executed a buyback of 200,000 shares for a total expenditure of HKD 1.4 million [1] - Executive director Chen Fei increased his stake by purchasing 200,000 shares [1]
药师帮(09885) - 翌日披露报表
2025-11-20 10:49
FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司(「香港聯交所」)證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露,必須填妥第一章節 。 表格類別: 股票 狀態: 新提交 公司名稱: 藥師幫股份有限公司 (於開曼群島註冊成立之有限公司) 呈交日期: 2025年11月20日 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 09885 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份(不包括庫存股份)變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份(不包 ...
药师帮获执行董事陈飞增持20万股
Zhi Tong Cai Jing· 2025-11-20 10:34
Core Viewpoint - The company, Yaoshi Bang (09885), announced that executive director Chen Fei purchased a total of 200,000 shares in the open market on November 20, 2025, indicating confidence in the company's future and growth potential, as well as a long-term commitment to the company [1] Summary by Relevant Sections - **Share Purchase** - Executive director Chen Fei acquired 200,000 shares in the open market [1] - **Management Confidence** - The board of directors believes that the share purchase reflects Chen's confidence in the company's prospects and growth potential [1] - **Long-term Commitment** - The share acquisition demonstrates Chen's long-term commitment to the company [1]
药师帮11月20日斥资139.72万港元回购20万股
Zhi Tong Cai Jing· 2025-11-20 10:34
Core Viewpoint - The company, Yaoshi Bang (09885), has initiated a share buyback program, indicating confidence in its long-term growth and market performance, as the current stock price is perceived to be undervalued compared to its true business potential [1] Summary by Relevant Sections - **Share Buyback Details** - The company repurchased a total of 200,000 shares on November 20, 2025, under the 2025 share buyback authorization [1] - The total amount spent on the buyback was approximately HKD 1.3972 million, excluding commissions and other expenses, with an average repurchase price of HKD 6.9859 per share [1] - **Management's Perspective** - The board believes that the current stock price does not adequately reflect the company's business prospects [1] - The share buyback plan is seen as a demonstration of confidence from the board and senior management regarding the company's long-term growth and market performance [1] - The board asserts that the buyback plan aligns with the overall best interests of the company and its shareholders [1]